Fosamax Cost in Michigan 2026: Alendronate Prices, Insurance, and Medicaid Coverage

What Does Fosamax (Alendronate) Actually Cost in Michigan in 2026?

Generic alendronate 70 mg tablets cost approximately $15 per month at Michigan retail pharmacies when purchased as a cash-pay prescription in 2026. The brand-name Fosamax carries a manufacturer list price near $80 per month, but virtually no patient needs to pay that figure given the availability of generics and discount programs.

The price spread between brand and generic is large for a reason. Alendronate's patent expired in 2008, and multiple manufacturers now produce the 70 mg weekly tablet. The FDA maintains a current list of approved generic alendronate products on its Orange Book database [1]. At chains such as Meijer, Walmart, and Kroger pharmacies across Michigan, the 4-tablet (28-day) supply of generic alendronate 70 mg often rings up between $10 and $18 before any discount card is applied.

Discount card platforms can compress the price further. GoodRx, RxSaver, and NeedyMeds each negotiate contracted rates with pharmacy benefit managers. At several Ann Arbor and Grand Rapids pharmacies reviewed in early 2025, GoodRx coupon prices for alendronate 70 mg (4 tablets) ranged from $9 to $14 [2]. The savings card from the drug's originator, Merck, applies only to brand Fosamax and is subject to eligibility restrictions; most commercially insured Michigan patients will simply fill the generic instead.

The fracture-prevention case for alendronate is not in doubt. The Fracture Intervention Trial (FIT, JAMA 1998, N=2,027) demonstrated that alendronate reduced clinical vertebral fractures by 55% and hip fractures by 47% over 3 years in postmenopausal women with low bone density [3]. That level of protection, priced at $15/month, makes alendronate one of the highest-value prescriptions in outpatient medicine.

How Michigan Medicaid Covers Alendronate (Fosamax)

Michigan Medicaid (Healthy Michigan Plan and traditional Medicaid) covers alendronate with a prior authorization (PA) requirement. The PA is not a denial, it is a documentation step your prescriber completes to confirm the diagnosis and that you meet standard criteria.

To meet PA criteria, most Michigan Medicaid plans require a documented diagnosis of osteoporosis or osteopenia, or a qualifying fragility fracture, or a dual-energy X-ray absorptiometry (DXA) T-score at or below -2.5 [4]. The American College of Endocrinology recommends pharmacotherapy initiation at a T-score of -2.5 or below, or at -1.0 to -2.5 with additional risk factors [5]. Once PA is granted, covered enrollees typically pay a nominal copay of $1 to $4 per fill, and some Healthy Michigan Plan enrollees pay nothing.

The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation, BHOF) states in its 2022 clinical practice guidelines: "Antiresorptive therapy with bisphosphonates is the recommended first-line pharmacologic treatment for most patients at high fracture risk" [6]. That guideline language directly supports a Medicaid PA request.

Michigan Medicaid also covers DXA scans with a frequency limit of one scan every 23 months for most enrollees. Getting a DXA before requesting the PA smooths the authorization process considerably [7].

If your PA is initially denied, Michigan law gives you the right to an expedited internal appeal within 72 hours for time-sensitive medications, and a standard appeal within 30 days for non-urgent cases. Your prescriber can submit a peer-to-peer review call with the plan's medical director, which resolves the majority of initial denials.

Is Compounded Alendronate Legal in Michigan?

Compounded alendronate is legal in Michigan when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription from a Michigan-licensed prescriber. No federal or state regulation currently prohibits the compounding of alendronate for an individual patient.

The distinction between 503A and 503B pharmacies matters here. Section 503A of the Federal Food, Drug, and Cosmetic Act covers traditional compounding pharmacies that prepare medications for individual patients on receipt of a prescription [8]. Section 503B applies to outsourcing facilities that compound in bulk without individual prescriptions. Alendronate compounding for individual patients at a 503A pharmacy is permissible; 503B bulk compounding of alendronate without a shortage designation is a separate, more restricted category [9].

Why would a patient want compounded alendronate when commercial generic tablets cost $15/month? A few legitimate clinical reasons exist. Some patients have documented intolerances to the excipients in commercial tablets. Others need a dose or formulation (such as a liquid suspension for swallowing difficulties) that is not commercially available. In those situations, a 503A pharmacist can prepare a custom formulation, and some HealthRX-partnered pharmacy programs cover the cost at $0 out-of-pocket for qualifying patients.

The FDA's guidance on compounding from bulk drug substances notes that compounders must use active pharmaceutical ingredients (APIs) that appear on FDA's approved API list or are sourced from an FDA-registered facility [10]. Prescribers and patients in Michigan should confirm the compounding pharmacy holds a current Michigan Board of Pharmacy license, which is searchable on the state's online license verification portal.

Which Insurance Plans Cover Alendronate in Michigan?

Most commercial insurance plans sold in Michigan cover generic alendronate on their formularies, typically at Tier 1 or Tier 2. Tier 1 copays in Michigan ACA marketplace plans average $5 to $15 per fill; Tier 2 copays average $15 to $45. Brand Fosamax sits on Tier 3 or Tier 4 at most plans, producing copays of $40 to $90 per fill or a coinsurance percentage, which is why the generic is the practical choice for nearly all insured patients.

The following major insurance carriers active in Michigan cover generic alendronate as of 2025 formulary filings: Blue Cross Blue Shield of Michigan (BCBSM), Priority Health, Molina Healthcare of Michigan, HAP (Health Alliance Plan), and McLaren Health Plan [11]. Medicare Part D also covers alendronate; the Low Income Subsidy (LIS/Extra Help) program reduces the cost to a nominal copay of $4.50 or less for qualifying beneficiaries [12].

Medicare Part B does not cover oral bisphosphonates as a rule, because Part B covers injected or infused drugs administered in clinical settings. Intravenous zoledronic acid (Reclast), by contrast, is covered under Part B when administered in a provider's office, a relevant comparison for patients who cannot tolerate oral dosing [13].

Employer-sponsored plans operating in Michigan under ERISA are subject to federal (not state) formulary rules, so their formularies vary more widely. Employees should download their Summary of Benefits and Coverage (SBC) or call the pharmacy benefit manager phone number on their insurance card to confirm tier placement.

How to Get Alendronate via Telehealth in Michigan

A telehealth prescription for alendronate is fully legal in Michigan. Alendronate is not a controlled substance, so no in-person examination requirement applies under Michigan's controlled substance telehealth rules. A licensed Michigan prescriber (physician, nurse practitioner, or physician assistant with prescribing authority) may evaluate your DXA results, fracture history, and risk factors via video or telephone and issue a valid alendronate prescription [14].

Michigan's telehealth parity law (PA 0459 of 2020) requires commercial insurers to cover telehealth visits on the same basis as in-person visits for covered services. That parity extends to the evaluation and management visit that generates an alendronate prescription [15].

The clinical workup before starting alendronate typically includes a serum calcium, 25-hydroxyvitamin D level, and kidney function panel. Patients with a creatinine clearance below 35 mL/min should not use alendronate due to accumulation risk; the FDA label carries this contraindication explicitly [16]. A telehealth prescriber can review these labs from prior bloodwork or order them at a local Michigan lab (Quest, LabCorp, or hospital outpatient labs) before writing the prescription.

Correct administration technique also matters. Alendronate 70 mg must be taken on an empty stomach with at least 6 to 8 ounces of plain water, and the patient must remain upright for 30 minutes afterward to reduce esophageal irritation risk. A telehealth provider can review these instructions during the visit and document patient education in the chart.

What Are the Cheapest Ways to Get Alendronate in Michigan?

The cheapest path to alendronate in Michigan depends on your insurance status. Here is a cost ladder from highest to lowest out-of-pocket.

Uninsured or underinsured: Use a GoodRx, RxSaver, or Blink Health coupon at a Michigan pharmacy. Expect to pay $9 to $18 for a 4-tablet (28-day) supply of generic alendronate 70 mg. Meijer's $4 generic program historically has included alendronate, though formulary lists change; call your local Meijer pharmacy to confirm current pricing [2].

Michigan Medicaid (with PA): Once prior authorization is approved, your copay is $1 to $4 per fill, and Healthy Michigan Plan enrollees at or below income thresholds pay $0.

Medicare Part D with LIS/Extra Help: Copay is $4.50 or less per fill in 2026 under the Low Income Subsidy benchmark benefit structure [12].

Commercial insurance (Tier 1): Copay of $5 to $15 per fill with most Michigan plans.

503A compounded alendronate (qualifying patients): $0 out-of-pocket when dispensed through programs covering the compounding cost, for patients who qualify on clinical grounds (documented intolerance to commercial formulations or need for a non-standard dose).

The Merck patient assistance program (PAP) for brand Fosamax provides free medication to uninsured or underinsured patients who meet income eligibility criteria, typically at or below 200% to 400% of the federal poverty level. The application is submitted by the prescriber through the Merck Engage program. Given that generic alendronate costs $15/month cash-pay, the PAP is most useful for patients who specifically require brand Fosamax for a documented clinical reason.

Understanding the Clinical Evidence Behind Alendronate

Alendronate belongs to the nitrogen-containing bisphosphonate class. It inhibits farnesyl pyrophosphate synthase in osteoclasts, suppressing bone resorption and increasing bone mineral density (BMD) at the lumbar spine, hip, and femoral neck [17].

The FIT trial (JAMA 1998, N=2,027) remains the foundational efficacy reference. Over 3 years of treatment with alendronate 5 mg/day (later 10 mg/day), women with femoral neck T-scores of -1.6 or lower experienced a 47% reduction in hip fractures (relative risk 0.53 to 95% CI 0.31 to 0.90, P<0.05) and a 55% reduction in clinical vertebral fractures compared to placebo [3]. The FLEX extension trial (JAMA 2006, N=1,099) followed FIT participants for an additional 5 years and found that women who discontinued alendronate after 5 years maintained most BMD gains and had fracture rates similar to those who continued, with the exception of clinical vertebral fractures, which were reduced in the continuing group [18].

The American Association of Clinical Endocrinology (AACE) 2020 guidelines place alendronate among the recommended first-line agents for postmenopausal osteoporosis, citing its 10-year safety record and low cost as factors supporting broad use [5]. For men with osteoporosis, the FDA approved alendronate 10 mg daily or 70 mg weekly, with the key male trial demonstrating a 7.1% increase in lumbar spine BMD versus 1.5% for placebo over 2 years [16].

Osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF) are the two most discussed rare adverse events. ONJ incidence in patients taking oral bisphosphonates for osteoporosis (not cancer) is estimated at 1 in 10,000 to 1 in 100,000 patient-years, a very different risk profile from the 1 in 10 to 1 in 100 risk seen with high-dose IV bisphosphonates in oncology settings [19]. AFF risk increases with treatment duration beyond 5 years, which is why most guidelines recommend a bisphosphonate drug holiday after 5 years in lower-risk patients [20].

Monitoring, Drug Holidays, and Long-Term Use in Michigan Patients

After initiating alendronate, a repeat DXA is typically ordered at 2 years to assess response. The Endocrine Society's 2019 fracture risk management guideline recommends reassessment of fracture risk after 3 to 5 years of bisphosphonate therapy to determine whether a drug holiday is appropriate [21].

Michigan Medicaid covers follow-up DXA scans at the once-every-23-months frequency noted earlier. Private insurance plans generally follow similar intervals, aligned with USPSTF screening recommendations for women aged 65 and older and for younger women with elevated fracture risk [7].

A drug holiday of 1 to 2 years after 5 years of alendronate is appropriate for lower-risk patients (T-score above -2.5 after treatment, no prior hip or vertebral fracture). Higher-risk patients may benefit from continued therapy or transition to an anabolic agent such as teriparatide or abaloparatide before cycling back to a bisphosphonate [21]. This decision is individualized and requires a prescriber familiar with current guidelines.

During a drug holiday, bone turnover markers (serum CTX or urine NTX) can help track residual bisphosphonate effect. Alendronate's half-life in bone exceeds 10 years, so protective effects persist even after stopping [17].

Alendronate Dosing and Administration: What Michigan Patients Must Know

The standard outpatient dose is alendronate 70 mg once weekly for osteoporosis treatment, or 35 mg once weekly for osteoporosis prevention in postmenopausal women not yet at the treatment threshold [16]. A 10 mg once-daily formulation exists but is rarely used now that the weekly tablet is available and pharmacokinetically equivalent.

Administration rules are strict. The tablet must be swallowed whole with 6 to 8 oz of plain water (not coffee, juice, or mineral water). The patient must not eat, drink anything other than plain water, or take other medications for at least 30 minutes after the dose. Remaining upright (sitting or standing, not reclining) for that 30-minute window is required to minimize esophageal exposure.

Upper GI side effects, including esophageal irritation and heartburn, are the most common reasons patients discontinue oral bisphosphonates. Patients with active esophageal disorders, including strictures or achalasia, should not use alendronate. The FDA label lists Barrett's esophagus as a condition requiring caution, though it is not an absolute contraindication [16].

Calcium and vitamin D adequacy supports treatment response. The BHOF recommends 1,000 to 1 to 200 mg of elemental calcium daily (preferably from dietary sources) and 800 to 1 to 000 IU of vitamin D3 daily for adults on bisphosphonate therapy [6]. Supplemental calcium should not be taken within 30 minutes of the alendronate dose, as divalent cations impair bisphosphonate absorption.